

Novotech presents to Chinese biotechs on 3 key benefits of early stage clinical trials in Australia

Shanghai, China – December 2016:

Novotech presented to a number of biotechnology companies based at China's [SuZhou BioBay](#) industrial park, on accessing [Australia's R&D Refund Scheme](#) and the regulatory benefits available when undertaking early stage clinical trials in Australia.

During the seminar, Novotech provided insights into how it supports its clients through the Australian start-up submission and approval process.

[Click to download a copy of the Frost and Sullivan White Paper 'Australia: Preferred Destination for Early Phase Clinical Trials'](#).

For more information, click [here](#) to contact a Novotech representative.



*Novotech Country Manager Mr Alex Ling,
based in China*

About Novotech - www.novotech-cro.com

Established in 1996 and headquartered in Sydney, Novotech has a strong presence in the Asia Pacific region, running clinical trials in all key regional markets including Australia, New Zealand, China, Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand and India.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and submissions, clinical monitoring, data management, statistical analysis, report write-up to ICH requirements, project management and vendor management.

Novotech also has worldwide reach through the company's network of strategic partners. Novotech - described by Frost & Sullivan as the best in its industry class for Australia-based CROs and recipient of the ARCS ANZ Clinical Trials award 'Best CRO'- brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area.